Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0YPVKH
ADC Name	Pertuzumab zuvotolimod
Synonyms	SBT6050; pertuzumab zuvotolimod Click to Show/Hide
Organization	Silverback Therapeutics, Inc.; ARS Pharmaceuticals, Inc.
Drug Status	Phase 1/2
Indication	In total 1 Indication(s) HER2(+) solid tumors [ICD11:2A00-2A0Z\|2B50-2F9Z] Phase 1
Structure
	3D MOL	2D MOL
Antibody Name	Pertuzumab		Antibody Info
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)		Antigen Info
Payload Name	Maytansinoid derivative		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Undisclosed
Conjugate Type	Random conjugation through reduced inter-chain cysteines.
Puchem SID	472422606 , 461453647 , 476001025
ChEBI ID	CHEMBL5095143

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Objective Response Rate (ORR)	NCT04460456	Phase 1	A phase 1/1b, open-label, dose escalation and expansion study of SBT6050 alone and in combination with PD-1 inhibitors in subjects with advanced solid tumors expressing HER2.
Undisclosed	NCT05091528	Phase 1	An open-label, phase 1/2, dose-escalation and expansion study of SBT6050 combined with other HER2-directed therapies in subjects with pretreated unresectable locally advanced and/or metastatic HER2-expressing or HER2-amplified cancers. Click to Show/Hide

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Objective Response Rate (ORR)	7.10%
Patients Enrolled	Patients have HER2-expressing or amplified solid tumors.
Administration Dosage	0.60 mg/kg administered Q2 weeks.
*Related Clinical Trial*
NCT Number	NCT04460456	Clinical Status	Phase 1
Clinical Description	A phase 1/1b, open-label, dose escalation and expansion study of SBT6050 alone and in combination with PD-1 inhibitors in subjects with advanced solid tumors expressing HER2.
Experiment 2 Reporting the Activity Date of This ADC				[2]
*Related Clinical Trial*
NCT Number	NCT05091528	Clinical Status	Phase 1
Clinical Description	An open-label, phase 1/2, dose-escalation and expansion study of SBT6050 combined with other HER2-directed therapies in subjects with pretreated unresectable locally advanced and/or metastatic HER2-expressing or HER2-amplified cancers.

References

Ref 1	A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results. 2020 Dec 7.
Ref 2	An Open-label, Phase 1/2, Dose-escalation and Expansion Study of SBT6050 Combined With Other HER2-directed Therapies in Subjects With Pretreated Unresectable Locally Advanced and/or Metastatic HER2-expressing or HER2-amplified Cancers, NCT05091528